A potential problem of autologous transplantation in the treatment of multiple myeloma (MM) is the infusion of tumor cells. CD34
haematological malignancies. 5, 6 Clonotypic B cells have been demonstrated in autologous blood/bone marrow stem cells in MM [7] [8] [9] [10] [11] and a correlation between autografting with heavily contaminated material and relapse has been suggested in MM and other diseases. 9, 12 Purging of transplant material to reduce malignant contamination may involve treatment of patients either by radiation, chemical or immunological means prior to collection of autologous cells in order to achieve an in vivo purging effect. 5,13-15. In vivo purging in autologous transplantation was first used by Chopra et al 16 in the treatment of acute leukaemia and lymphoma. The authors suggested that haemopoietic cells collected after the first high-dose therapy may have lower tumour contamination and therefore be more suitable for rescue following a second round of high-dose therapy. In MM there is also evidence that a prolonged high-dose treatment can reduce tumour burden and exert an in vivo purging effect on PBSC collections. 4, 13, 17 PBSC collections harvested at the end of a chemotherapy sequence contain significantly fewer plasma cells than those harvested upfront after a single high-dose drug administration.
Alternatively, a number of methods for removing tumour cells in vitro have been developed. 12, 14, [18] [19] [20] Myeloma contamination in the autograft may be reduced by purging with a panel of anti-B cell antibodies, [21] [22] [23] or by positive selection for haemopoietic progenitor cells. 15, [23] [24] [25] Bone marrow myeloma cells lack CD34 expression 26 but clonally related cells expressing CD34 have been demonstrated in stem cell harvests. 27 The suggestion that the myeloma stem cell is CD34
+ is yet to be confirmed 28, 29 and while clonally related cells have been detected in stem cell harvests their clonogenicity in vivo is unknown as they apparently do not proliferate in vitro. 30 Because myeloma cells lack uniform expression of B cell antigens CD34
+ selection of the graft may provide the best means of obtaining autologous haemopoietic support with a minimum of residual tumour contamination. 23, 26 The purging efficacy of CD34 + positive selection in MM has been demonstrated by a number of groups, with tumour depletion varying from 1.5 to 4 logs. [31] [32] [33] While there was frequently persistent contamination of the CD34 + fraction, the number of contaminating cells appeared low. Whether the reinfusion of such small numbers of tumour cells contribute to relapse is not known.
Since the efficacy of either in vivo treatment or purging, or in vitro purging, in reducing tumour burden had been demonstrated in a number of diseases, we initiated this study to investigate whether a combination of both approaches would improve the efficacy of purging and yield an autologous transplant material with a significantly reduced tumour cell contamination. The treatment schedule comprised two sequential cycles of chemotherapy and haemopoietic growth factor mobilisation, CD34 + selection, and transplantation following high-dose therapy. Thirtyfour patients were enrolled in this study that exploits an in vivo purging effect by collecting stem cells after high-dose therapy and uses CD34
+ selection as a means of in vitro purging.
Materials and methods

Patients and treatment protocol
Twenty patients treated at the Bone Marrow Transplant Unit of the Royal Adelaide Hospital and 14 patients treated at the Bone Marrow Transplant Unit of The Royal Prince Alfred Hospital were entered on this trial. The diagnosis and staging of multiple myeloma was based on that of Durie and Salmon. 34 Patients were eligible for this study if they were less than 65 years of age and had previously untreated disease, or had had less than two treatment regimens, and had advanced or progressive disease. There were five phases to the treatment protocol as illustrated in Figure  1 : (1) debulking chemotherapy using three cycles of VAD; Madison, NJ, USA) 5 g/kg/day followed by apheresis and CD34 + selection; (3) high-dose therapy with cyclophosphamide 4 g/m 2 i.v. and epirubicin 200 mg/m 2 i.v. followed by stem cell transplantation using CD34
+ -selected cells and GM-CSF 5 g/m 2 /day post transplantation for a second stem cell mobilisation followed by apheresis and CD34 + selection; (4) a second high-dose therapy with busulphan 1 mg/kg orally 6 h × 16 and melphalan 140 mg/m 2 i.v. followed by stem cell transplantation using CD34
+ -selected cells; (5) maintenance therapy with interferon-alpha 3 × 10 6 U/m 2 3×/week.
Antibodies
IgGFITC and IgGPE and CD19FITC were purchased from Dako (Glostrup, Denmark). HPCA2PE (CD34), Leu17PE (CD38), Leu19PE (CD56) were purchased from Becton Dickinson (Mountain View, CA, USA). KC56(T200)FITC was purchased from Coulter (Miami, FL, USA).
Harvest of stem cells
Leukapheresis was performed using a Fenwal CS3000Plus continuous flow blood cell separator (Baxter Healthcare, Deerfield, IL, USA) as previously reported. 35 Leukapheresis was commenced when the total white count reached 1 × + selected prior to cryopreservation. Leukapheresis and CD34
+ cell selection continued until at least 2 × 10 6 CD34 + -enriched cells had been stored. For the second stem cell mobilisation all leukapheresis products were CD34
+ selected prior to cryopreservation, and leukapheresis continued until at least 2 × 10 6 /kg CD34 + -enriched cells had been stored.
Leukapheresis products from 21 patients who were entered on the trial were CD34 + selected using the semi-automated Nexell Isolex 300 Cell Selection System (Nexell Therapeutics, Irvine, CA, USA). Leukapheresis products from the remaining patients were CD34
+ selected using the Nexell Isolex 300i Cell Selection System (Nexell Therapeutics). In most cases cells harvested on 2 consecutive days were pooled for selection, with the aim of processing a maximum of 4 × 10 10 (for the Isolex 300) to 8 × 10 10 (for the Isolex 300i) MNC for each selection (the maximum cell number validated by the manufacturer). Cells collected by leukapheresis on the first day were kept overnight with 20% added autologous plasma at 4°C on a rotator and pooled with cells harvested the next day. CD34
+ selection was performed according to the manufacturer's instructions. When selection was performed using the Isolex 300 system the pooled cells were depleted of platelets prior to treatment by washing twice at 400 g for 10 min. CD34
+ -enriched cells were washed twice in working buffer before cryopreservation. When selection was performed using the Isolex 300i, no treatment (other than filtration to remove cell clumps) of the pooled leukapheresis products was required prior to selection. The CD34 + -enriched product was collected in a 100 ml volume, and was concentrated by centrifugation prior to cryopreservation.
Cryopreservation of stem cells
Stem cells, either unmanipulated or CD34
+ -selected, were cryopreserved in 10% dimethyl sulphoxide and 20% autologous plasma in 20 ml volumes in 50 ml cryocyte freezing containers (Nexell Therapeutics).
Estimation of myeloid progenitors
CFU-GM were assayed as described previously. 35 Briefly, 0.1 to 1 × 10 5 MNC or CD34 + -depleted cells or 2 × 10 3 CD34 + -enriched cells were plated in triplicate in 1 ml IMDM, containing 25% foetal bovine serum (FBS; PA Biologicals, Sydney, Australia), 0.33% agar (Difco, MI, USA), and 7.5% v/v human placental conditioned medium. Aggregates of Ͼ50 cells after 14 days of incubation at 37°C in a humidified atmosphere with 5% CO 2 were scored as CFU-GM and expressed as colonies per 10 6 cells plated or per ml blood.
Flow cytometric analysis
Quantitation of CD34
+ cells: A two-colour immunofluorescence staining procedure was used for the study of surface marker expression as previously described. 36 Briefly, 5 × 10 5 MNC or CD34 + -depleted cells or 2 × 10 5 CD34 + -enriched cells were incubated with PE-or FITC-conjugated antibodies or isotype controls for 30 min at room temperature, washed, and resuspended in 1% formalin fixative and refrigerated until analysis. Samples were analysed within 48 h using a Coulter Profile II flow cytometer or Coulter XL flow cytometer (Coulter Electronics) with standard optical configuration, and an Argon laser emitting 488 nm at 15 mW. Listmode data from 100 000 events were collected, taking into account the whole nucleated cell population, and excluding from the acquisition gate debris and cell aggregates. In all cases staining with a specific monoclonal antibody was compared with its appropriate isotype/fluorochrome matched control. CD34 + cells were enumerated by back-gating for CD45 expression and side scatter, true CD34 + cells being characterised by low-density CD45 expression and low side scatter.
Quantitation of CD38
++ cells: Enumeration of CD38 ++ cell populations was carried out using Elite listmode analysis package version 4.01 or XL analysis package 2.0 (Coulter); CD38 ++ cells were discriminated on the PE side-scatter dot plot with intensity of staining greater than 10 2 .
Statistical analysis
Descriptive statistics, linear regression, Spearman rank correlation coefficient, Mann-Whitney U test, Kruskal-Wallis one-way ANOVA and Fisher exact test were calculated using Analyse-It for Excel (Analyse-It Software, UK) and Excel version 7.0 for Windows.
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Results
Patients
Thirty-four patients, 12 females and 22 males, 30 to 65 years old (median 51 years) were enrolled in this trial. Patient details and clinical responses are reported elsewhere. 37 Briefly, 32 patients completed the first cycle of mobilisation, stem cell harvest and CD34
+ selection with 22 patients proceeding to the first high-dose therapy and stem cell infusion. Of the 21 patients who proceeded to a second cycle of mobilisation, stem cell harvest and CD34 + selection, 15 proceeded to the second high-dose therapy and stem cell infusion.
Progenitor cell enrichment by CD34
+ selection
Selection of CD34
+ cells: Ninety-seven CD34 + selection procedures were performed, with a median of 2 (range 1-5) selection procedures/patient/mobilisation cycle, the results of which are summarised in Table 1 . Selection led to a 189-fold reduction in MNC with a procedure-related loss of 13%. Viability of the enriched cells was consistently in excess of 90% as measured by trypan blue exclusion. Microbiological contamination was not detected in any of the CD34 + -enriched samples. To limit the number of selection procedures, cells harvested on 2 consecutive days were pooled for selection. We found no detrimental effect of overnight storage on either cell viability or levels of CD34 + cells in the leukapheresis product, or on the yield or purity of CD34
+ cells in the enriched product, in contrast to Koc et al.
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The CD34
+ -enriched fraction contained a median 0.8 × 10 8 CD34 + cells and was enriched 68-fold from 1.3% to 88.6%. An example of dot plots of pre-selection and CD34 + -enriched fractions is shown in Figure 2 . The purity of the enriched population significantly correlated with the CD34 + percentage of the pre-selection fraction (r s = 0.67, P Ͻ 0.0001, Spearman rank correlation). If there were more than 0.5% CD34 + cells in the pre-selection fraction then 74% (56 of 76) of the selected products had a purity in excess of 80% (P Ͻ 0.0001, Fisher exact test) while 59% (45 of 76) had a purity in excess of 90% (P Ͻ 0.0001, Fisher exact test). The yield of CD34 + cells in the CD34 + -enriched fraction was 42% while 20% were recovered in the CD34 + -depleted fraction; there was a 38% procedurerelated loss of CD34 + cells. The yield was inversely correlated with the number of CD34 + cells loaded on to the selection system (r s = −0.38, P = 0.0001, Spearman rank correlation). If more than 1.7 × 10 8 CD34 + cells were processed only 15% (8 of 52) had CD34 + cell yields greater than 50% (P = 0.0002, Fisher exact test). There was no correlation between CD34 + yield and purity. There was an 86-fold enrichment of myeloid colonyforming cells (CFU-GM), and a significant correlation between the enrichment of CFU-GM and the initial CFU-GM/10 6 (r s = 0.61, P Ͻ 0.0001, Spearman rank correlation). The yield of CFU-GM showed a weak but significant inverse correlation with the starting number of CFU-GM cells (r s = −0.26, P = 0.04, Spearman rank correlation).
CD34
+ selection of autologous peripheral blood stem cells PG Dyson et al Sixty-nine of the 97 selection procedures were performed using the semi-automated Nexell Isolex 300 Cell Selection System and 28 were performed using the Nexell Isolex 300i Cell Selection System. Although the yield was similar, the purity of the CD34 + -enriched fraction was significantly higher when selection was performed on the Nexell Isolex 300i (median CD34 + = 95.8%, range 96.6-99.3%) rather than the Nexell Isolex 300 (median CD34 + = 95.8%, range 35-99%) (P Ͻ 0.0001, Kruskal-Wallis ANOVA). However, selection on the Nexell Isolex 300i was performed on samples which had a significantly higher CD34
+ percentage (P = 0.0002, Kruskal-Wallis ANOVA) and total number of CD34
+ cells (P = 0.029, Kruskal-Wallis ANOVA). The 189-fold reduction in MNC numbers following CD34 + selection allowed the product to be cryopreserved in a small volume. For this trial patients at transplant received a median 40 ml (range 20-120 ml, n = 47) of CD34 + -selected cells. During the same period 24 MM patients who underwent autologous transplantation with unselected cells received a median 180 ml (range 70-575 ml) infusion volume. Thus the infusion volume received by patients on this trial was reduced 4.5-fold (P Ͻ 0.0001 Kruskal-Wallis ANOVA) compared with patients receiving unselected cells. Although similar numbers of MNC/kg were processed for both mobilisation cycles there were twice as many CD34 + cells/kg/selection (P = 0.0002, Kruskal-Wallis ANOVA) and almost twice as many CFU-GM/kg/selection (P = 0.03, Mann-Whitney U test) in the selected product for the first mobilisation cycle compared with the second. There were similar numbers of selection procedures/patient performed for both mobilisation cycles (Table 2) , however, in the first cycle sufficient CD34
+ -enriched cells were collected in two selection procedures in 89% (24 of 27) of patients compared with 65% (13 of 20) of patients in the second cycle (P Ͻ 0.0001, Fisher exact test). Table 2 shows that on a per patient basis there were 1.4-fold more CD34
+ cells in the pre-selection product (P = 0.03, Mann-Whitney U test) and in the CD34 + -enriched product (P = 0.006, Mann-Whitney U test) during the first mobilisation cycle than during the second mobilisation cycle. The level of CD34 + cells in the pre-selection product was 2.5-fold higher for the first mobilisation cycle than for the second mobilisation (P = 0.006, Kruskal-Wallis ANOVA), and the levels of CFU-GM in the pre-selection product were 2.7-fold higher for the first mobilisation cycle than for the second mobilisation (P = 0.08, Mann-Whitney U test). There was no significant difference in the percentage yield of CD34
+ cells in the enriched fraction between the two mobilisation cycles. For the 18 patients who successfully completed two cycles of mobilisation and selection the level of CD34 + cells in the pre-selection product the first mobilisation cycle correlated significantly with the level in the pre-selection product in the second mobilisation (r s = 0.77, P = 0.0002, Spearman rank correlation). As shown in Figure 3 the circulating levels of CD34 + cells in the first cycle of mobilisation were higher in 11 patients who went on to successfully complete two mobilisation cycles than in four patients who did not (P = 0.026, Kruskal-Wallis ANOVA). In 93% (13 of 14) of patients in whom the circulating level of CD34 
Depletion of CD38
++ cells by CD34 + selection
Validation of CD38 ++ as a means of identifying plasma cells: Plasma cells were identified by high expression of
Bone Marrow Transplantation the CD38 antigen (CD38 ++ ). In a preliminary study we found that of the cells expressing cytoplasmic immunoglobulin a median of 77% (range 59-89%, n = 4) were contained within the CD38 ++ fraction and a median 94% (range 90-100%) of CD38 ++ cells showed cytoplasmic expression of either or light chains. Light chain restriction studies by other groups have also validated high CD38 expression as a means of identifying plasma cells 40, 41 that enables detection of as few as one tumour cell per 10 3 -10 4 total cells. 13, 40 To validate the use of CD38
++ to quantitate plasma cells we enumerated plasma cells in bone marrow smears from 20 patients and compared these estimates in a double-blind manner with the numbers of CD38 ++ cells estimated by flow cytometry in the corresponding marrow aspirate. There was significant linear correlation between plasma cell levels and the levels of CD38 ++ cells (r 2 = 0.82, P Ͻ 0.0001) (Figure 4a) .
The sensitivity of CD38 ++ cell quantitation was tested by analysing 5 × 10 5 normal peripheral blood mononuclear cells to which were added either 0.01%, 0.05%, 0.1%, 0.5%, 1%, 5% or 10% WL2 cells 42 -which express high Results are calculated for the total transplant product for each patient and are expressed as median and range. 
levels of CD38
++ -using an automated cell deposition unit on a Facstar plus (Becton Dickinson, San Jose, CA, USA). The samples were coded for analysis and 100 000 events were collected for each sample, CD38
++ events being those with fluorescence intensity beyond 10 2 . This analysis demonstrated a significant correlation between actual and nominal levels of CD38 ++ cells (r 2 = 1, P Ͻ 0.0001, linear regression) for levels between 0.01% and 10% (Figure 4b) .
In 14 mobilised stem cell collections from mobilised normal donors and acute leukaemia patients in remission the median level of CD38 ++ cells was 0.014%, with 95% confidence limits being 0.002-0.05%. We have therefore set 0.05% as the lower level of sensitivity for the measurement of CD38 ++ cells, which is similar to the range of reported sensitivities of 0.01% and 0.1%. 13, 40 Accordingly we have recorded values of 0.05% for all levels of CD38 ++ cells between 0% and 0.05% with the result that the calculated depletion of CD38 ++ cells is underestimated when the level of CD38
++ cells is below 0.05% in the CD34 + -selected product. We have also excluded from our analysis results where less than 20 positive events were detected.
Depletion of CD38
++ cells: An example of dot plots of preselection and CD34
+ -enriched fractions stained with an anti-CD38 antibody is shown in Figure 2 . The depletion of CD38 ++ cells following CD34 + selection in 89 procedures is illustrated in Figure 5 . The level of CD38 ++ cells was reduced 3.6-fold (Table 1 ) and there was a 2.7-log reduction in the number of CD38
++ cells in the CD34 + -enriched product, a net removal of 99.8%. The depletion of CD38
++ cells significantly correlated with both the initial CD38
++ percentage (r s = 0.52, P Ͻ 0.0001, Spearman rank correlation) and the starting number of CD38
++ cells (r s = 0.63, P Ͻ 0.0001, Spearman rank correlation), and with the number of cells processed (r s = 0.32, P = 0.0025, Spearman rank correlation). The CD38 ++ cell dose infused at transplantation was reduced 387-fold from a median 1.2 × 10 6 /kg to a median 0.0031 × 10 6 /kg (P Ͻ 0.0001, MannWhitney U test).
Comparison of CD38
++ cell depletion in the first and second mobilisation cycles: Figure 6a and b show the number of CD38 ++ cells collected in the leukapheresis product in each of the two mobilisation cycles in the patients who completed two cycles. The number of CD38 ++ cells collected in the leukapheresis product was 2.5 × 10 6 /kg in the first mobilisation, five-fold higher than the 0.5 × 10 6 /kg in the second mobilisation (P = 0.007, Kruskal-Wallis ANOVA).
By way of comparison, CD34
+ selection (Figure 6c ) led to a 500-fold reduction in the dose of CD38 ++ cells transplanted. There was significantly greater CD38
++ depletion as result of CD34
+ selection in the first mobilisation cycle (616-fold) than in the second (186-fold) (P = 0.03, Kruskal-Wallis ANOVA) so that the number of CD38
++ cells in the CD34 + -enriched product was similar for both mobilisation cycles.
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Discussion
A number of groups have attempted to reduce malignant contamination of peripheral blood stem cells in MM by in vivo purging while others have used the in vitro purging approach to deplete contaminating plasma cells. In this study we report a significant reduction in the malignant contamination of PBSC autografts in MM using a treatment schedule that combines the in vivo purging effect of sequential cycles of high-dose chemotherapy, stem cell mobilisations and transplantations, with in vitro purging by CD34 + selection of blood stem cell products prior to transplantation.
During the study, 97 CD34 + selection procedures were performed resulting in a 68-fold enrichment of CD34
+ and a 86-fold enrichment of CFU-GM. The yield and purity of progenitor cells in the selected product was correlated significantly with the level of these cells in the product prior to selection. To limit the number of selection procedures, cells harvested on 2 consecutive days were pooled for selection with no detrimental effect on cell viability or levels of CD34
+ cells pre-and post-selection. Although the number of MNC processed in each selection procedure was within the manufacturer's recommended dose, there was considerable variability in both purity and yield of CD34 + -enriched cells. We found the number of CD34 + cells processed to be the best indicator of CD34 + cell yield -CD34 + cell yields in excess of 50% were only consistently achieved so long as the CD34 + cell load was less than 1.7 × 10
. The level of CD34
+ cells in the leukapheresis product was the best indicator of purity of the CD34 + -enriched fraction. If the percentage of CD34 + cells was greater than 0.5% then the purity of the enriched product was greater than 80% in 74% of procedures and exceeded 90% in 59% of procedures.
Of the 97 selection procedures 28 were performed using the fully automated Nexell Isolex 300i. This has a number of technical advantages over the Nexell Isolex 300 including a completely closed system for processing and no requirement for prior processing of leukapheresis product thereby minimising the risk of product contamination during processing, less operator dependence, reduced processing time and the capacity to process twice the number of mononuclear cells. The clinical scale CD34 + selection procedure was not labour intensive, and consistently yielded an enriched product of high purity and viability and free of microbial contamination. As a result of the volume reduction these patients were infused with lower volumes of dimethyl sulphoxide thereby reducing the likely occurrence of the associated side-effects. 38 Flow cytometric methods provided a simple, fast and reliable means to assess the effect of CD34 + selection on the tumour contamination of stem cell products enabling detection of as few as 1/1000-1/10 000 tumour cells. 13, 41 Although molecular techniques based on polymerase chain reaction are more sensitive allowing detection of as few as 1/1000-1/10 000 tumour cells quantitative analysis is complex and labour intensive. 43 It also remains to be determined if the added sensitivity of molecular techniques is of clinical significance. We and others 40, 41 ++ cells added in predetermined numbers to blood MNC to demonstrate linearity and sensitivity of the assay; and (3) the determination of a normal range for CD38
++ cells in peripheral blood to establish 0.05% as the lower limit of sensitivity for the detection of malignant cells. This value is in close agreement with reported levels. 13, 40 The extent of depletion of CD38 ++ cells as a result of CD34 + selection correlated with the burden of these cells in the leukapheresis product. As a result of CD34
+ selection there were 500-fold less CD38
++ cells in the CD34 + -enriched product compared with the leukapheresis product and a 2.7-log reduction in the dose of CD38
++ cells received at transplant. This is a purging efficiency comparable to that reported in the published literature for MM patients. 15, 23, 24, 31 Our results also showed that it was possible to predict which patients would have low progenitor cell numbers harvested in the second cycle of mobilisation. Those who reached circulating levels of CD34 + cells in excess of 40/l in the first mobilisation cycle had a much better chance of achieving a successful second stem cell harvest in this study.
An in vivo purging effect of sequential cycles of highdose chemotherapy is demonstrated by the five-fold reduction in CD38
++ cells in the leukapheresis product in the second mobilisation compared with the first. The numbers of CD38 ++ cells in the CD34 + -enriched product were similar for both mobilisation cycles. Hence, although there was a significant in vivo purging effect resulting from mobilisation of stem cells following sequential cycles of high-dose therapy this was obscured by the much greater effect of in vitro purging.
In conclusion, we have demonstrated the efficacy of combining the in vivo purging effect of sequential cycles of high-dose chemotherapy, stem cell mobilisation and transplantation with in vitro purging by CD34 + selection in reducing malignant contamination of stem cell autografts in MM. There was a five-fold reduction in the tumour contamination of leukapheresis products which was achieved by sequential cycles of high-dose therapy while clinical scale CD34
+ selection consistently yielded an enriched product of high purity and viability with a 500-fold reduction of tumour contamination. The 100-fold greater tumour reduction by CD34
+ selection compared with the effect of sequential high-dose therapy suggests that equally effective tumour purging -both residual disease and in the autograft -could be achieved if a single round of stem cell harvests and CD34
+ selection was performed and used in tandem transplants. The increased safety of such a protocol would render it applicable to a wider range of patients.
